I've been pretty consistent with my message too Hung. New CEO? Well, he's only part of the board that ultimately makes the decisions. I'm not even sure I can fully judge his job at this point. We still need some more patience.
I don't know whether SRPT can start addressing this before approval (my gut says 'no') but it is probable this will be a difficult battle with insurers.
I think we are all in for the potential. But instead of executing on potential, it seems like we just broaden our intellectual property, more potential. It also doesn't seem that they are moving with any urgency. My biggest concern, which is shared with others, is that other immunotherapy companies are moving faster into trials and are developing relationships with BP (i.e. JUNO, NLNK, ADXS), while little happens here. The grants are great--I applaud them. I like the publishing, but man, move forward already, start p3, make another deal (even if not perfect) with BP.
Sentiment: Strong Buy
This is what CME courses say today. Will be interesting what the question says in a few years. Landscape will change dramatically:
The diagnosis of Duchenne muscular dystrophy (DMD) should be the physician’s first thought in a 3-5 year old boy with difficulty running/jumping, toe walking, large calves, neck weakness, a partial Gower’s sign, and a CK level greater than3000 U/L. Corticosteroids should be offered to all boys with DMD. Corticosteroids prolong walking; transiently increase, and then slow the decline in, muscle strength; reduce falls; improve pulmonary measures; decrease scoliosis; and may improve cardiac and cognitive function. The timing for initiation of steroids, and the specific dosage to be used remain undefined. Alternate regimens of weekend-only dosing have shown similar benefits with fewer long term side effects of steroid use (growth and adrenal suppresion, bone health, hypertension).
The only thing that concerns me is that CYTK has noted on several occasions that the trial wasn't powered to show significance on cardiac function. In other words, it'll likely show a trend. The uncertainty for me is that the street may view this as a failure (which any scientist would laugh at), but it's their game. If Amgen decides to move to p3, this may alter the view a bit, but I find the street to be a stubborn bunch (noteworthy is that we haven't come close to recovering from the drop from Benefit ALS but we are proceeding to p3 after getting the FDA's nod). Of course, I'm hoping for the best. One of the things I've learned over the last 15 years of investing is that perception is sometimes more important than truth (at least in the short to intermediate term). GL.
Sentiment: Strong Buy
I agree enabeler. I hope we don't find out but the price action with a statistically significant PPS of 7.5 mths is hard to predict (but I suspect it'll be muted). I would feel even better about our situation if I had not lived through the bad decisions that MMM and EXEL have made.
Thats my understanding too but I wanted a good grasp of this... in essence, if converted at set price, would add X number of shares to market (250 million worth in this case). Essentially becomes a dilution if I understand this correctly. I would think this is baked into share price though and has impacted demand historically
I'm trying to understand how the convertible debt issue with EXEL may impact stock price after (let's say for argument sake) positive news on Meteor. I fear more manipulation. I read an article from AF and crew back in 2012, which was a bit tough to follow. Can anyone recommend any short article on the topic? Thanks in advance. AlexP
Dan, I've never seen them go to these lengths.
Unfortunately, I've also never seen justice for cases of fraud like this. Case in point, AF continues to write
I read your warning and expected this. As many times as I see this, it will never be palatable. GL snowflakeformationxy
The S.A. writer is an idiot. I dont understand how this FUD Scam works over and over. All of a sudden some random writer who's background you dont know has an opinion worth considering?
By letting these options trades affect your choices, you're implying that you believe they know something we don't.there's always been a fair amount of skepticism surrounding the stock and this should be evidenced by the large short position. it doesn't help that the company has never acted in a shareholder friendly fashion. I will keep my investment as is for now. GL